1152311-62-0 Usage
Description
Tezacaftor (VX-661) is an oral medication for cystic fibrosis (CF) developed by Vertex Pharmaceuticals. In a combination therapy formulation called Symdeko (tezacaftor plus ivacaftor), it is approved in the U.S. and Canada for CF patients, ages 12 and older, who have two copies of the F508del mutation in the CFTR gene and one minimal function mutation. Symdeko is approved and marketed in the EU as Symkevi.Tezacaftor is not approved as a stand-alone treatment, but as part of a combination therapy.
Uses
Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis.
Definition
VX-661 is an investigational compound that promotes the maturation of delta F508 mutants of the cystic fibrosis transmembrane conductance regulator (CFTR). Delta F508 CFTR represents a class of CFTR mutation that is characterized by impaired processing of misfolded CFTR proteins and reduced accumulation of the protein at the cell surface. VX-661 is intended to facilitate trafficking of CFTR to the epithelial cell membrane. It may be combined with the CFTR potentiator ivacaftor (Item No. 15145) to stimulate both CFTR accumulation and opening at the apical epithelial surface.
Biochem/physiol Actions
VX-661 is another cystic fibrosis transmembrane conductance regulator (CFTR) corrector in development for the treatment of cystic fibrosis.
in vitro
VX-661, is CFTR modulator that is potentially useful for treatment of cystic fibrosis. VX-661 corrects F508del-CFTR trafficking and increases F508del-CFTR protein activity in vitro.
references
[1] s. donaldson, j. pilewski, m. griese, q. dong, p.-s. lee, for the vx11–661-101 study group. ws7.3 vx-661, an investigational cftr corrector, in combination with ivacaftor, a cftr potentiator, in patients with cf and homozygous for the f508del-cftr mutation: interim analysis. journal of cystic fibrosis, volume 12, supplement 1, june 2013, page s14
Check Digit Verification of cas no
The CAS Registry Mumber 1152311-62-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,2,3,1 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1152311-62:
(9*1)+(8*1)+(7*5)+(6*2)+(5*3)+(4*1)+(3*1)+(2*6)+(1*2)=100
100 % 10 = 0
So 1152311-62-0 is a valid CAS Registry Number.
InChI:InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1
1152311-62-0Relevant articles and documents
NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR
-
, (2021/08/14)
The present invention generally relates to processes for preparation of Tezacaftor and pharmaceutical composition comprising the same. The present invention also encompasses novel intermediates of tezacaftor, processes for its preparation and use of said intermediates in the preparation of tezacaftor.
SOLID FORMS OF TEZACAFTOR, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page/Page column 34, (2021/05/21)
The present invention relates to solid forms of Tezacaftor, including its co-crystals, solvates, hydrates and/or polymorphs, processes for their preparation, pharmaceutical compositions containing the same and use of such solid forms of Tezacaftor in the preparation of another form of Tezacaftor such as amorphous form of Tezacaftor. The present invention also provides stable amorphous form of Tezacaftor, its preparation and pharmaceutical composition containing the same.
Preparation method of 5-substituted cyclopropyl formylamino indole derivative
-
Paragraph 0107; 0108, (2020/10/21)
The invention provides a preparation method of a 5-substituted cyclopropyl formylamino indole derivative, and particularly relates to a preparation method of Tezaacaftor. 2-nitro-4-fluoro-5-halogenated phenylacetonitrile is used as an initial raw material, and the Tezaacaftor is obtained through an ammonia substitution reaction, an amidation reaction, a dehydration condensation reaction, a reduction cyclization reaction-elimination reaction, a ring-opening substitution reaction and a catalytic hydrogenolysis reaction. The method has the advantages of cheap and easily available raw materials, short reaction steps, simple and safe preparation method, easy realization and low cost; the design of the route provided by the invention fully combines the inherent characteristics of functional group reaction, ensures proper reaction activity and high selectivity of each step of unit, and provides essential guarantee for high yield and high purity of the product; the method is high in route atomeconomy, high in product yield and purity, low in waste acid and waste water yield, environmentally friendly and suitable for industrial production.